Advanced Prostate Cancer COE

How to Treat Men with pN1 Prostate Cancer - Presentation - Alberto Bossi

Details
Alberto Bossi presented on the recommended treatment for men with pathological node-positive prostate cancer. These patients are becoming more common as surgery is being performed on a higher proportion of high-risk patients with positive nodes. Highlighting unanswered questions regarding the treatment of these patients following surgery, Dr. Alberto Bossi mentions several studies that have assess...

Disadvantages of PSMA PET/CT in Advanced Prostate Cancer Imaging Presentation - Ian Davis

Details
As a follow-up to Dr. Stefano Fanti’s presentation on the advantages of PSMA PET-CT imaging, Dr. Ian Davis from Melbourne discussed some of the pitfalls and disadvantages of PSMA PET-CT in advanced prostate cancer imaging. Biography: Professor Ian Davis, MB, BS, Ph.D., FRAC,P FAChPM, is a medical oncologist, cancer immunologist, clinician-scientist, and NHMRC Practitioner Fellow. He is Professor o...

Radiation Therapy Options for Men with Newly Diagnosed cN1 cM0 Prostate Cancer - Mack Roach

Details
Mack Roach presents on radiotherapy options for patients with clinically node-positive prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Dr. Roach touches on areas such as the optimal candidate for salvage lymph node dissection (SLND) for nodal recurrence of prostate cancer, the role of adding ADT to radiotherapy, and the NRG/RTOG 9413 study which showed whole pelv...

How Best to Treat cN1 Prostate Cancer - Karim Fizazi

Details
Karim Fizazi summarizes how best to treat node-positive (cN+) prostate cancer patients at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). There are over 20 randomized controlled trials in localized and advanced prostate cancer that have been published according to Dr. Fizazi, yet he notes, none have been published in the setting of node-positive prostate cancer. In this presentatio...

Ethnicity and Prognosis of Prostate Cancer - Christopher Logothetis

Details
Christopher Logothetis presents on the ethnicity and prognosis of prostate cancer during the Regional Care (Demographic and Environmental Factors) Session at the Advanced Prostate Cancer Consensus Conference the (APCCC 2019). Dr. Logothetis discusses the significant difference in the incidence and mortality of prostate cancer worldwide. There are greater differences in the incidence rates than in...

Testosterone Measurement – Which Test and When? - Martin Gleave

Details
Martin Gleave presents on the topic of testosterone measurement and its various nuances in the context of advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Testosterone measurement is important as androgens are the drivers of activity of the androgen receptor. Dr. Gleave supports the periodic assessment of testosterone levels to ensure castrate levels, wit...

The Aging Population: Oncogeriatric Assessment and Treatment Considerations Presentation - Joe O'Sullivan

Details
Joe O'Sullivan presented on the aging population and how to properly assess them in the context of prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The age at diagnosis of prostate cancer has been increasing over time, while prostate cancer mortality has been decreasing. Aging is associated with increased comorbidities, which may affect the tolerance of therapies...

The Management of Sexuality and Incontinence in Advanced Prostate Cancer Presentation - Inge Van Oort

Details
Inge van Oort presented the topic of managing sexuality and incontinence issues in patients with advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). When assessing sexual symptoms she references the EAU guidelines on sexual activity and the percentage of prostate cancer patients that will receive androgen deprivation therapy (ADT) at some point in the diseas...

A Subgroup Analysis of mCRPC Clinical Trials Presentation - Susan Halabi

Details
In this presentation, Susan Halabi discusses the implications of subgroup analyses in metastatic castration-resistant prostate cancer (mCRPC) trials during the management of CRPC session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The challenge, according to Dr. Halabi, is balancing the dichotomy of the danger of interpreting subgroup analysis with applying overall results o...

The Future of Advanced Prostate Cancer Management: In Locally Advanced Prostate Cancer Presentation - Alberto Briganti

Details
At the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Alberto Briganti shares his thoughts on where he would like to see the treatment of locally advanced prostate cancer in the future. Dr. Briganti's presentation covers 4 major areas where he views opportunity for progress: the intensification of tailored multi-modal approaches, image-guided surgery, the use of novel tools to improve...